Entries by admin

Cancer Vaccines Market Growing at 27% CAGR to 2019

The Global Cancer Vaccines Market 2015-2019 report says use of vaccines in combination with other therapies is propelling the growth of cancer vaccines market across the world in addition to frequent occurrence of different types of cancer and the introduction of various cancer vaccines. Complete report on cancer vaccines market spread across 64 pages, talking […]

Soon-Shiong’s NantCell hauls in another $100M for immuno-oncology R&D

NantCell, one of billionaire entrepreneur Patrick Soon-Shiong’s biotech ventures, raised $100 million in equity cash, moving forward with some in-licensed immuno-oncology treatments. The company’s latest fundraise comes on the heels of a $75 million round revealed in June, each coming from a single, undisclosed investor. Like all of Soon-Shiong’s biotech endeavors, NantCell says little outside […]

Agenus mortgages some vaccine royalties for $115M in R&D cash

Agenus ($AGEN) is trading away future royalties on a GlaxoSmithKline ($GSK)-partnered vaccine adjuvant in exchange for up to $115 million, planning to invest the proceeds in its growing pipeline of immuno-oncology treatments. Under a royalty financing deal, Agenus will hand over the rights to QS-21, used alongside GSK vaccines for malaria and shingles, to an […]

Bristol-Myers’ latest PD-1 win could pave the path to earlier use

Bristol Myers-Squibb ($BMY), a leader among companies at work in immuno-oncology, is pressing for wider use of its lead treatment with new data showing the injected drug could succeed as part of a first-line treatment in lung cancer. In a Phase Ib study, a combination of Bristol-Myers’ immunotherapies Opdivo and Yervoy charted overall response rates […]